Farmas USA

GALE

issuance of 28,000,000 shares of common stock at a purchase price per share of $0.45 in a registered direct offering, and warrants to purchase up to 14,000,000 shares of common stock with an exercise price of $0.65 per share in a concurrent private placement, resulting in gross proceeds to the Company of $12,600,000. The warrants are initially exercisable six months and one day following issuance and have a term of five years from the date of issuance. The closing of the sale of securities is expected to take place on or about July 13, 2016, subject to certain customary closing conditions.

The Company intends to use the net proceeds from this offering to fund its clinical trials of its product candidates, to augment its working capital, and for general corporate purposes.

ya sabemos porque subia, no?
"o la subian" ...
GALE

US economy adds a whopping 287,000 jobs

http://finance.yahoo.com/news/june-nonfarm-payrolls-jobs-unemployment-000000315.html

FUTUROS BIEN VERDES :)

GALE

Que necesitaban pasta estaba clarísimo, más si tienen que devolver la deuda esa de 25,5M vinculada al estudio Present. Del sec filing es destacable que van abrir investigación interna sobre la decisión del IDMC (aunque no veo que llegue a ningún lado, pero veremos, hablan de meses...)

Our Phase 3 PRESENT clinical trial has been stopped due to futility and though we are conducting an investigation of the causes for the failure of the clinical trial, we are not certain that the investigation will result in the reason(s) for the failure.
On June 27, 2016, the Independent Data Monitoring Committee conducting the pre-planned interim analysis of the PRESENT Trial recommended that we stop the clinical trial because of futility. We are conducting an investigation of the causes of the failure of the trial, which may take a number of months. Once the investigation has been concluded, we may or may not know the reasons for the failure of the clinical trial. As we are conducting the investigation, we have stopped any further dosing of the patients. The investigation may cause us to unblind the data of the clinical trial. Because we will be investigating the causes of the failure of the clinical trial, the PRESENT Trial may no longer likely be considered a registrational clinical trial. Even if we determine the causes of the failure, NeuVax may never be approved for the treatment of patients with Node positive HER2 negative breast cancer.

Se te echaba de menos, mugi.

Unos días fuera de vacaciones totalmente desconectado. Lunes/Martes ya estaré por aquí! Hoy solo un momentico aprovechando que tengo un PC con conexión...

Que cosa más curiosa y no me dí cuenta ayer. Las tres que llevo cerraron planas......

NVAX, EXEL, CASC

Bueno, he puesto orden a 7,25$, 1,5k para acompañarte framus. A ver como se da.

Aún no me ha entrado.

PACB